ALIS

DRUG2 trials

Sponsors

Insmed Incorporated

Conditions

Mycobacterium Infections, Nontuberculous

Phase 3

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

CompletedNCT04677543

Insmed IncorporatedMycobacterium Infections, Nontuberculous

Start: 2020-12-22End: 2023-05-09Updated: 2024-06-28

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

CompletedNCT04677569

Insmed IncorporatedMycobacterium Infections, Nontuberculous

Start: 2021-04-01End: 2026-01-15Updated: 2026-02-03

Related Papers

Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial.

2026-04-01

Psychometric validation of the PROMIS Fatigue-Short Form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies

Journal of Patient-Reported Outcomes2025-10-16

Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE Study

Pulmonary Therapy2025-04-081 citations

Concurrent Randomized, Double-Blind, Placebo-Controlled Trials to Validate Patient-Reported Outcome (PRO) Instruments and Assess Clinical Benefit of Treatment in Adults with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium AviumComplex (MAC)

2021-05-01